300 related articles for article (PubMed ID: 10839615)
1. Divergent neuroendocrine differentiation in prostatic carcinoma.
di Sant' Agnese PA
Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine differentiation in prostatic malignancy.
di Sant'Agnese PA; Cockett AT
Cancer; 1996 Jul; 78(2):357-61. PubMed ID: 8674017
[TBL] [Abstract][Full Text] [Related]
4. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
[TBL] [Abstract][Full Text] [Related]
5. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A
J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
7. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
[TBL] [Abstract][Full Text] [Related]
8. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
9. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
Abrahamsson PA; Cockett AT; di Sant'Agnese PA
Prostate Suppl; 1998; 8():37-42. PubMed ID: 9690662
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in prostate cancer.
Shariff AH; Ather MH
Urology; 2006 Jul; 68(1):2-8. PubMed ID: 16844446
[No Abstract] [Full Text] [Related]
13. Neuroendocrine differentiation in prostatic carcinoma: an update.
di Sant'Agnese PA
Prostate Suppl; 1998; 8():74-9. PubMed ID: 9690666
[TBL] [Abstract][Full Text] [Related]
14. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
15. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
[TBL] [Abstract][Full Text] [Related]
18. Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2.
Diaz M; Abdul M; Hoosein N
Prostate Suppl; 1998; 8():32-6. PubMed ID: 9690661
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
20. Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum.
Grabowski P; Schönfelder J; Ahnert-Hilger G; Foss HD; Heine B; Schindler I; Stein H; Berger G; Zeitz M; Scherübl H
Virchows Arch; 2002 Sep; 441(3):256-63. PubMed ID: 12242522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]